Amesite Reports Surge in Revenue Following Launch of AI-Native NurseMagic EMR

Reuters12-19
Amesite Reports Surge in Revenue Following Launch of AI-Native NurseMagic EMR

Amesite Inc. announced a series of revenue increases aligned with the rollout of its higher-value product tiers. Following the May 2025 launch of the Teams+ offering, the company reported a 2.4x increase in quarterly revenue. The introduction of the Enterprise tier in July 2025, which is priced based on patient census rather than individual users, resulted in an 82% increase in fourth quarter revenue. Additional expansion of Enterprise capabilities and industry outreach led to a further 69% quarter-over-quarter revenue increase in the first quarter of fiscal 2026. The company also announced the launch of the NurseMagic™ EMR, an AI-native, modular electronic medical record system, with customer onboarding expected to begin in January 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amesite Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604982) on December 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment